Therapeutics – Verséa


Verséa™ Biologics at the North American Neuromodulation Society 26th Annual Meeting

Members of our Verséa Biologics team (Sunil Panchal, MD, Chief Scientific Officer, Verséa Biologics; David Kloth, M.D., Medical Director, Verséa Biologics; and Bill Bigham, VP of Sales, Verséa Biologics) attended this year’s North American Neuromodulation Society 26th Annual Meeting. At the event they had a chance to present our innovative portfolio of Biologics products which...

Cannabinol (CBN) shows unique therapeutic potential in glaucoma

A recently published peer-reviewed scientific article “Cannabinol Modulates Neuroprotection and Intraocular Pressure: A Potential Multi-Target Therapeutic Intervention for Glaucoma” has provided insight into unique therapeutic potential of Cannabinol (CBN) for glaucoma treatment   The article, published in a leading international journal Biochimica et Biophysical Acta (BBA – Molecular Basis of Disease) (LINK to the article)...